Entering text into the input field will update the search result below

iBio, Inc. (IBIO) Announced iBioLaunch Platform’s Successful Production of Hookworm Vaccine Antigen

May 27, 2011 6:12 PM ETIBIO
Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

iBio, Inc., a biotechnology company that engages in the development of vaccines and therapeutic proteins, recently announced that its iBioLaunch™ Platform has successfully produced the hookworm-derived molecule, known as NaAPR1M-75. The Antigen will be evaluated as a potential vaccine candidate to be used for the human hookworm disease.

The success has been derived from the collaboration between iBio’s research partner, the Fraunhofer Center for Molecular Biotechnology (FCMB) and the Sabin Vaccine Institute. Production for the initial quantities of partially purified NaAPR1M-74 was completed last week at FCMB’s pilot manufacturing facility that utilizes the iBioLaunch Technology. The product was then transferred to Walter Reed Army Institute for Research (WRAIR) for the last stage of purification to create enough material to start Phase 1 clinical trials.

“We are very pleased with the success in expressing a pilot batch of this antigen in collaboration with iBio and FCMB,” said Dr. Peter Hotez, President of Sabin Vaccine Institute. “It has been extremely difficult to produce this protein effectively, as evidenced by multiple prior unsuccessful attempts using traditional production systems.”

“The expression of this complex protein with the iBioLaunch™ Platform not only moves us closer to a solution for hundreds of millions of people who suffer from hookworm, but also bodes well for other complex protein expression challenges,” said Dr. Philip Russell, a member of the Board of Trustees of Sabin Vaccine Institute and member of the Board of Directors of iBio.

Clinical trials will be administered by the Sabin Vaccine Institute’s Human Hookworm Initiative (HHVI). The HHVI, which was established in 2000 with funding from the Bill & Melinda Gates Foundation and with the additional support from the Dutch Ministry of Foreign Affairs and the Brazilian Ministry of Health, is the first and the only program that strives to reduce the prevalence of the human hookworm infection with the aid of research and development, timely result announcements, advocacy, and innovation.
For more information on the company and its products, visit their company website: ibioinc.com

Please see disclaimer on QualityStocks website: disclaimer.qualitystocks.net

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.